Navigation Links
Visceral Leishmaniasis: Successful Vaccine Trial In Dogs

g-term protection against visceral leishmaniasis.

Although this vaccine’s effectiveness has been shown only on a limited number of animals, it is a further step towards protection of dogs against this disease. These results, confirmed indeed by the first, highly encouraging, data from a large-scale clinical trial currently under way (phase III), are promising for efforts to reduce transmission of leishmaniasis to humans. They also point to new lines of investigation for elaborating a possible human vaccine. An integrated research project, involving several IRD groups (2), has just been set up in India, to work on this. It should lead to an assessment of the effectiveness of such a vaccine in humans.

(1) The finding of these proteins furthermore necessitated the development, achieved in 1992, of suitable culture media (patented), with the attached proteins removed. The media normally used ijn fact contain many protein-containing compounds (serumalbumins, albumins etc.) which prevent specific isolation of the proteins excreted by the parasite. References : Lemesre J.L., Blanc M.P., Grébaut P., Zilberfard V. et Carrière V. (1994). Culture continue de formes amastigotes de Leishmanies en condition axénique. Réalisation du cycle évolutif in vitro. Médecine et Armées, 22 (1), 99 and Merlen T, Sereno D, Brajon N. and Lemesre J.L. (1999). Leishmania Spp: completely defined medium without serum and macromolecules (CDM/LP) for the continuous in vitro cultivation of infective promastigote forms. Am. J. Trop. Med. Hyg., 60 (1), 41-50. Brevets : Lemesre J.L. (1993). "Procédé de culture in vitro de différents stades parasitaires obtenus et applications biologiques". Brevet français, FR n° 93 05779 ; Lemesre J.L. (1994)."Method for the culture in vitro of different stages of tissue parasites".Brevet international, PCT/FR N° 94/00577.

(2) The project, entitled « Study of the host and parasite factors determining the outcome of visceral leishmaniasis: applica
'"/>

Source:Institut de Recherche Pour le D茅veloppement


Page: 1 2 3 4

Related biology news :

1. Successful Test Of Single Molecule Switch Opens The Door To Biomolecular Electronics
2. Penn Surgeons Use Completely Robotic Surgery to Successfully Treat Prostate Cancer
3. Successful cell engineering may lead to mad cow prevention, say researchers
4. Successful transplantation from pig embryos to mice
5. Successful lung cancer surgery not enough to break nicotine dependence in many smokers
6. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
7. Live Recombinant Adenovirus Vaccine Technique Explored
8. Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer
9. NIAID Initiates Trial of Experimental Avian Flu Vaccine
10. Study Models Impact Of Anthrax Vaccine
11. New Insights Into HIV Immunity Suggest Alternative Approach to Vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Visceral Leishmaniasis Successful Vaccine Trial Dogs

(Date:7/30/2015)... MOUNTAIN VIEW, Calif. , July 30, 2015 ... products and services for gene function analysis and ... CRISPR Guide RNA (sgRNA) Knockout Library targeting all ... to specifically and permanently "knock out" a gene,s ... library provides a high throughput screening tool so ...
(Date:7/23/2015)... July 23, 2015 Aware, Inc. (NASDAQ: AWRE ... reported financial results for its second quarter ended June 30, ... 2015 was $4.5 million, a decrease of 33% compared to ... in the second quarter of 2015 was $0.3 million, or ... $0.04 per diluted share, in the same period a year ...
(Date:7/21/2015)... Connecticut , July 21, 2015  NXT-ID, ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet, announces that it has filed ... System and Method. This invention ... not only authorizes an account, but also the ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4
... pair of proteins that work in concert to restart the ... The Hawley Lab has described the dual actions ... awakens the long-dormant egg, allowing for production of a mature ... 4, 2007 issue of PLoS Biology. The long ...
... from the John Innes Centre have proven that by ... and delivering it with an existing antibiotic they can ... transfer company PBL, the scientists have launched a spin-out ... The DNA sequence acts as a decoy, disrupting gene ...
... severe weather and climate change joined forces to study ... severe storms in the future and discovered a dramatic ... the United States. The Purdue University-led team used ... formation of severe thunderstorms - those that produce flooding, ...
Cached Biology News:Stowers Institute's Hawley Lab identifies factors responsible for restart of meiotic cycle 2Decoy makes sitting duck of superbugs 2Research forecasts increased chances for stormy weather 2Research forecasts increased chances for stormy weather 3Research forecasts increased chances for stormy weather 4Research forecasts increased chances for stormy weather 5
(Date:7/31/2015)... ... July 31, 2015 , ... Global ... and premium industry insights on the global resorcinol industry. The report highlights the ... of vivid market scenarios and analysis of primary and secondary inputs from the ...
(Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm is proud to announce ... gluten in foods, has been accepted by AOAC International as Official First Action ... Fermented Cereal-Based Products by R5 Competitive ELISA,” based on a specific monoclonal antibody ...
(Date:7/30/2015)... ATLANTA , July 30, 2015 ... leaders to the 2015 AACC Annual Meeting & ... from July 26–30. The meeting showcased revolutionary ... improves the ability of healthcare providers to diagnose ... get effective medical treatment. As ...
(Date:7/30/2015)... Grenoble, France and Dallas, TX, USA (PRWEB) , ... ... ... manufacturer of innovative nano and microsystems, has appointed Francois Vieillard as Sales & ... & Marketing at executive positions, Francois Vieillard will be responsible for reinforcing Tronics’ ...
Breaking Biology Technology:Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Tronics appoints Francois Vieillard as Sales and Marketing Director 2
... VIENNA, Va., June 4 In response to ... is providing an,update on the construction of its ... built out, will comprise 73,000 square,feet and will ... product. This dedicated facility will produce the Multikine ...
... Research, MELVILLE, N.Y., June 4 ... University,s Feinberg School of,Medicine announced the opening ... a partnership that brings improved research,capabilities to ... development. One of only three such centers ...
... (OTC Bulletin Board: BSTC.OB) today announced that it,sold ... at $13 per,share with aggregate proceeds to BioSpecifics ... group on May 30, 2008. The shares were ... premium over the market price., BioSpecifics Technologies ...
Cached Biology Technology:CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter 2CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter 3Nikon Instruments Opens New Imaging Center at Northwestern University 2Nikon Instruments Opens New Imaging Center at Northwestern University 3
... scale kinase profiling, quantitative measurement of ... research built on the flexible and ... These microarrays are available as part ... - Peptide Microarray Service. ...
... commonly used technique for studying protein function ... on SDS-PAGE and transferred to a membrane ... are probed with specific antibodies. Unlike nucleic ... Southern and Northern blots, it has been ...
... for immunological studies, vaccine development, and ... and powerful Paraflo microfluidic on-chip synthesis ... part of our comprehensive Epitope Peptide ... Content Probe content is completely ...
... built on the flexible and powerful ... microarrays are available as part of ... Custom Probe Content ... Thousands of customer specified peptide sequences ...
Biology Products: